ANAB
Anaptysbio, Inc.
A biotechnology company built around a platform that mimics somatic hypermutation — the natural process the human immune system uses to mature antibodies against threats. Founded in 2005 in San Diego by antibody engineers Tillman Gerngross and Nicholas Lydon, it developed drugs including dostarlimab (Jemperli), a cancer immunotherapy licensed to GSK. In 2026 it spun off its drug-development arm and now focuses on collecting royalties from its former programs. Its name nods to the antibody biology at its roots.
CUSIP: 032724106HealthcareUS1 holder
Total Value
$45.13M
Total Shares
799.9K
Net Share Change
-30.3K
Activity
1 selling
Investor
Value
Shares
Weight
Change
